Evidence map›Paper›PMID 40943068›Full record

ArticleInternational journal of molecular sciences2025

Claudin-1 Contributes to Gastrointestinal Stromal Tumors (GIST) Resistance to Imatinib Mesylate (IM) via Regulation of FGFR-Signaling.

Sergei Boichuk, Firyuza Bikinieva, Pavel Dunaev, Aigul Galembikova, Ekaterina Mikheeva, Elena Valeeva, Shinjit Mani, Natalia Khromova, Pavel Kopnin, Leyla Shigapova and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sergei BoichukDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0003-2415-1084
Firyuza BikinievaDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0002-9012-6525
Pavel DunaevDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0002-5449-4435
Aigul GalembikovaDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0002-0293-2974
Ekaterina MikheevaDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0001-8213-427X
Elena ValeevaCentral Research Laboratory, Kazan State Medical University, Kazan 420012, Russia.
Shinjit ManiDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0003-0490-0383
Natalia KhromovaCytogenetics Laboratory, Carcinogenesis Institute, N.N. Blokhin National Medical Research Center of Oncology, Moscow 115458, Russia.ORCID 0000-0001-8348-6760
Pavel KopninCytogenetics Laboratory, Carcinogenesis Institute, N.N. Blokhin National Medical Research Center of Oncology, Moscow 115458, Russia.ORCID 0000-0002-2078-4274
Leyla ShigapovaRegulatory Genomics Research Center, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.ORCID 0000-0001-6292-6560
Ruslan DeviatiiarovRegulatory Genomics Research Center, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.ORCID 0000-0003-0019-2076
Elena ShagimardanovaLIFT-Life Improvement by Future Technologies Institute, Moscow 121205, Russia.ORCID 0000-0003-2339-261X
Sergey RyzhkinDepartment of Radiotherapy and Radiology, Faculty of Surgery, Russian Medical Academy of Continuous Professional Education, Moscow 125993, Russia.ORCID 0000-0003-2595-353X
Alexey SabirovTatarstan Cancer Center, Kazan 420029, Russia.

Funding

Russian Science Foundation 24-25-00418
6 · The paper itself

Abstract

We previously demonstrated that the activation of FGFR signaling in GIST may be a mechanism of GIST resistance to imatinib mesylate (IM). We show here that IM-resistant GIST cells lacking secondary

Indexed as

Claudin-1Drug Resistance, NeoplasmGastrointestinal NeoplasmsGastrointestinal Stromal TumorsImatinib MesylateSignal TransductionAnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMicePhenylurea CompoundsProto-Oncogene Proteins c-kitAntineoplastic AgentsClaudin-1CLDN1 protein, humanImatinib MesylateinfigratinibPhenylurea CompoundsProto-Oncogene Proteins c-kitPyrimidinesclaudin 1gastrointestinal stromal tumors (GIST)imatinib mesylate (IM)resistance

Identifiers

PMID40943068
PMCPMC12428531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.